CTIC : Insider Transactions for Cti Biopharma Corporation | J3SG

Sign in:	Email	Password save:

		Company Reports
Find Symbol

Recent: Companies Filers Institutions

Membership is free, please Sign Up.

My Recent Searches

Help

Roster

Institutions

Add To Portfolo/Alerts

Get Insiders for :

Cti Biopharma Corporation (CTIC)

$9.09 0.00 (0.00%) as of 4:30 Thu 6/22

Download

Exchange:

Nasdaq National Market

Security Type:

Common

Shares Out:

126,890,000

Market Cap:

1.15(B)

Last Volume:

0

Avg Vol:

0

52 Week Range:

$4.79 - $9.1

Level I Sector:

Health Care

Level II Sector:

Drugs

Level III Sector:

Biotechnology

Member Indexes:

	NASDAQ BIOTECHNOLOGY		NASDAQ COMPOSITE
	NASDAQ NNM COMPOSITE

Rankings:

Insider 3 Months : -

Insider 6 Months : -

Insider 3/6 Months : -

Guru Rank Number : -

Guru Rank Value : -

Guru Occurances : -


6 Months 1 Year 2 Year

Company Profile CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies for blood-related cancers where there is an unmet medical need. Co. has one commercially approved product, VONJO™ (pacritinib), which has received approval in the U.S. by the U.S. Food and Drug Administration for the treatment of adult patients with intermediate or primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 x 10^9/L.

D/I:

D is for direct shares.
I is for indirect shares.

D/I refers to the Direct or Indirect shares traded vs. held.

Forms:

A Form 4 is a form filed by an insider to indicate a change in ownership.

A Form 3 is a form filed by an insider to indicate an initial ownership of a security.

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.

Actions:

B	Buy
S	Sell
OE	Option Exercised
A	Acquired
D	Disposed
AB	Automatic Buy
AS	Automatic Sell
IO	Initial Ownership

Download:

Download only Transactions Forms. (Default)

Download only Summary Infomation.

Download both Transactions and Summary Data

Summary (Direct Transactions Only)	3 Months	6 Months	12 Months	24 Months
Total Shares Bought	0	0	0	5,000
Total Buy Value	$0	$0	$0	$27,500
Total People Bought	0	0	0	1
Total Buy Transactions	0	0	0	1
Total Shares Sold	0	0	0	9,922,851
Total Sell Value	$0	$0	$0	$60,660,378
Total People Sold	0	0	0	5
Total Sell Transactions	0	0	0	29
End Date	2024-02-01	2023-10-31	2023-05-02	2022-05-02

Adjust Filter Settings

Records found: 229

Page 7 of 10

Filer's Name

Relation Title

Off-Dir-10%

D/I

Rank

3m +/-

Form

President and CEO

• • –

2015-09-30

4

S

$1.45

$289,340

D/D

(200,000)

3,221,519

-

EVP, Global Medical Affairs

• – –

2015-09-30

4

S

$1.45

$36,443

D/D

(25,000)

1,351,850

-

Nudelman Phillip M Phd

Director

– • –

2015-09-29

4

S

$1.45

$20,853

D/D

(14,380)

477,794

-

President and CEO

• • –

2015-09-29

4

S

$1.43

$570,840

D/D

(400,000)

3,421,519

-

Plunkett Matthew

EVP, Corporate Development

• – –

2015-09-29

4

S

$1.41

$106,052

D/D

(75,000)

650,084

-

EVP, Global Medical Affairs

• – –

2015-09-29

4

S

$1.38

$105,348

D/D

(75,000)

1,376,850

-

EVP, Finance & Administration

• – –

2015-09-29

4

S

$1.38

$239,541

D/D

(170,000)

941,347

-

EVP, Global Medical Affairs

• • –

2015-09-25

4

AS

$1.63

$24,584

D/D

(15,000)

1,451,850

-

EVP, Finance & Administration

• – –

2015-09-24

4

AS

$1.52

$15,200

D/D

(10,000)

1,111,347

-

Plunkett Matthew

EVP, Corporate Development

• – –

2015-09-24

4

AS

$1.52

$119,041

D/D

(75,869)

725,084

-

Plunkett Matthew

EVP, Corporate Development

• – –

2015-09-21

4

A

$0.00

$0

D/D

151,739

800,953

-

President and CEO

• • –

2015-09-21

4

A

$0.00

$0

D/D

507,603

3,821,519

-

EVP, Finance & Administration

• – –

2015-09-21

4

A

$0.00

$0

D/D

205,931

1,121,347

-

EVP, Global Medical Affairs

• • –

2015-09-21

4

A

$0.00

$0

D/D

205,931

1,466,850

-

Plunkett Matthew

EVP, Corporate Development

• – –

2015-09-04

4

AS

$1.53

$15,355

D/D

(10,000)

649,214

-

Plunkett Matthew

EVP, Corporate Development

• – –

2015-09-04

4

D

$1.52

$19,040

D/D

(12,526)

659,214

-

EVP, Global Medical Affairs

• • –

2015-08-28

4

AS

$1.55

$23,718

D/D

(15,000)

1,260,919

-

Plunkett Matthew

EVP, Corporate Development

• – –

2015-08-04

4

AS

$1.84

$18,426

D/D

(10,000)

671,740

-

Seeley Bruce J.

EVP, Chief Commercial Officer

• – –

2015-07-27

4

A

$0.00

$0

D/D

300,000

300,000

-

EVP, Global Medical Affairs

• • –

2015-07-24

4

S

$1.88

$28,664

D/D

(15,000)

1,275,919

-

EVP, Finance & Administration

• – –

2015-07-23

4

AS

$1.91

$19,100

D/D

(10,000)

915,416

-

Plunkett Matthew

EVP, Corporate Development

• – –

2015-07-06

4

AS

$1.92

$19,493

D/D

(10,000)

681,740

-

EVP, Global Medical Affairs

• • –

2015-06-26

4

AS

$2.04

$31,024

D/D

(15,000)

1,290,919

-

EVP, Finance & Administration

• – –

2015-06-25

4

AS

$2.18

$21,800

D/D

(10,000)

925,416

-

Plunkett Matthew

EVP, Corporate Development

• – –

2015-06-04

4

AS

$2.05

$20,613

D/D

(10,000)

691,740

-

229 Records found	1 2 3 4 5 6 7 8 9 Next	Page 7 of 10

	Transaction Code Key:				Ownership Code Key
	B	- Buy	AB	- Automatic Buy	D	- Direct Ownership
	S	- Sell	AS	- Automatic Sell	I	- Indirect Ownership
	OE	- Options Exercised	A	- Acquired
	IO	- Initital Ownership	D	- Disposed

Copyright © 2024 j3sg.com | Disclaimer & Terms of use Products & Service About Us Contact Us

Summary:

Chart:

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.